US20020025344A1 - Ionic silver complex - Google Patents
Ionic silver complex Download PDFInfo
- Publication number
- US20020025344A1 US20020025344A1 US09/796,242 US79624201A US2002025344A1 US 20020025344 A1 US20020025344 A1 US 20020025344A1 US 79624201 A US79624201 A US 79624201A US 2002025344 A1 US2002025344 A1 US 2002025344A1
- Authority
- US
- United States
- Prior art keywords
- colloidal solution
- silver
- substantially non
- free
- ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 137
- 239000004332 silver Substances 0.000 title claims abstract description 137
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims description 96
- -1 silver ions Chemical class 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000008139 complexing agent Substances 0.000 claims abstract description 25
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 18
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 17
- 239000004615 ingredient Substances 0.000 claims abstract description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 28
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 20
- 229910001923 silver oxide Inorganic materials 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 150000001261 hydroxy acids Chemical class 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940071536 silver acetate Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000000243 solution Substances 0.000 description 43
- 150000002500 ions Chemical class 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000006196 drop Substances 0.000 description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940050931 potassium citrate monohydrate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 231100000936 topical exposure Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/06—Chelate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
Definitions
- This invention relates to solutions including complexed ionic silver. More particularly, it relates to solutions including complexed ionic silver wherein the solutions convey health benefits through their use or application.
- Silver has been known to act antimicrobially as an agent in and on the body of humans as well as other animals, and to be relatively non-toxic to mammalian cells when used in the minute quantities needed to be antimicrobially effective.
- the most effective form of silver for antimicrobial use is as ions in solution.
- Silver ions have been shown in the past to have antibacterial, antiviral and antifungal qualities, and to contribute directly to the regeneration of tissue. While the exact method by which silver ions perform these functions is not known, it is believed that they may (1) disrupt the respiratory functions, or (2) disrupt membrane functionality of single-celled microorganisms, or (3) link to the cell's DNA and disrupt cell functions. It is not conventionally understood why silver ions appear to some to be effective at regenerating tissue, which apparently involves more than acting as an antimicrobial agent.
- ionic silver substances have been undergoing a substantial resurgence in popularity, and are increasingly regarded as a reasonably safe and effective antimicrobial agent.
- Silver ion substances are increasingly being used in medical applications as well as by those seeking a natural alternative to traditional antibiotic medications.
- Ionic silver substances are being used in topical dressings to treat wounds and to prevent and treat infections. They are also being used for water supply sanitation for public utilities, for pharmaceutical equipment sanitation, and for killing germs including the germ that causes Legionnaires' Disease in the water systems of hospitals. Tooth brushes are now being introduced that release silver ions in order to fight oral bacteria.
- free silver defined as silver ions which are not part of a complex or compound, and are therefore biologically available, are delivered at once to the body, there is only opportunity for them to perform the antimicrobial function for an instant where they make contact with the body or the oral tissue before being rendered inactive.
- an antimicrobial ionic silver formulation has desirable characteristics that it gradually releases its silver content as free silver ions upon ingestion or upon topical application in a manner that is slow enough to sustain the antimicrobial functionality for a sufficient period of time while also being rapid enough to be substantially effective, that it facilitate mobility of the silver through the body upon oral ingestion prior to gradually releasing its silver content as available free silver ions, and that it be nontoxic to the body.
- Topical applications of ionic silver do not require a controlled, gradual release of silver ions to the degree that internal, oral ingestion applications require it because there is a lower presence of agents with which the silver ions can bind up and form complexes or compounds upon topical exposure as compared with ingestion for internal use.
- At least one product has been recently introduced that consists of a film dressing impregnated with a complex that gradually releases silver ions upon exposure to the body's chemistry.
- Colloidal silver is a substance which has been in use for about a hundred years. It provides a reasonable degree of controlled release and mobility of silver ions in and on the body. Colloidal silver is apparently made up of minute particles of silver, associated with silver ions that comprise a small percentage of such particles. The mass of these particles provide a degree of controlled, gradual release of silver ions as the body's chemistry breaks down these particles.
- the electrolysis process that is used to make most colloidal silver has substantial limitations and does not enable adequate consistency in terms of parts per million (PPM) of silver relative to the total solution by molar weight, particle size, or percentage of ions, for most desired applications. Additionally, purity of the substance is typically limited because electrolytes must usually be added to the water during the production method, the most common of which is sodium. Oxides typically form during production, often resulting in an undesirable yellow or brown color. Moreover, the potency of most electrically produced colloidal silver is inherently limited. After a concentration of approximately 5 PPM of silver (in some cases up to approximately 20 PPM of silver) is reached, the production method typically fails to continue yielding electron-deficient silver particles. The particles formed after such a concentration is reached are typically not capable of performing antimicrobial functions as do the particles that are initially produced prior to reaching this approximate level of total silver concentration (the aggregate of the complexed silver and the free, available silver in the water-based solution).
- PPM parts per million
- colloidal means “something suspended in a dissimilar medium,” and shelf life is, therefore, inherently limited because the colloidal silver particles gradually settle out of the water. Colloidal particles are not dissolved in the water medium; they are not in solution. The suspension is a result of, for example, Brownian motion which is insufficient to keep the particles from settling out over time. Some colloidal silver substances have stabilizing agents such as proteins added to the formula, but these tend to further hinder the availability of the silver ions to the body. What is therefore needed are compositions comprising silver ions, and methods of making and using such compositions, that address the aforementioned problems.
- the invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
- a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent overcomes many of the limitations inherent in the aforementioned forms of ionic silver substances and has wide application in and on the body.
- the inventive, substantially non-colloidal solution provides silver ion concentrations well above those typically provided by colloidal silver products.
- the production method provides a typically consistent formulation.
- the inventive formulation is highly stable, has many years of shelf life, and maintains its consistency and structure under a wide range of environmental conditions. Substantially wide concentration ranges of complexed silver are attainable without significantly compromising the desirable characteristics of the product.
- the composition of the invention efficiently provides for substantial mobility of the silver complex through the body and for controlled decomplexing of its silver content, whereupon it gradually releases silver as available free silver ions, upon introduction of the product to the body's chemistry internally through oral ingestion or upon topical application.
- the inventive, substantially non-colloidal solution is relatively nontoxic to the human body at typical doses.
- the inventive substantially non-colloidal solutions are made from ingredients comprising water, a source of free silver ions; and a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
- Water usable in the practice of this invention should be relatively pure. Suitable types of water include: deionized water, distilled water, reverse osmosis filtered water, reagent grade water and USP grade water suitable for use in pharmaceuticals.
- the water is desirably substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination.
- the source of silver ions may be virtually any compound or complex which includes silver ions as a constituent, from which those silver ions can be obtained in order to be complexed with the recited complexing agent or to become free silver ions as part of the inventive solution.
- Sources of silver ions comprise silver oxide, trisilver citrate, silver acetate, water soluble silver salts or any number of other sources of silver without departing from the scope of the invention.
- the source of silver ions is silver oxide (AgO).
- silver oxide eliminates a superfluous counter ion, hydroxide, which is innocuous since hydroxide is already present in the solution.
- the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent serves primarily to provide a “controlled release” of biologically active silver ions.
- complexing agent may be taken to mean an ionic material with which silver ions are complexed in such a manner that the complexing agent forms a weak bond with the silver ions wherein the missing electron position which is a characteristic of the silver ion is filled by an electron of the complexing agent.
- the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent may comprise a carboxylic acid, or a primary, secondary or tertiary amine.
- substantially non-toxic may be taken to mean that the recited complexing agent, when present in the inventive solution in usual amounts according to the invention, and when administered as part of the inventive solution in usual dosage amounts of the inventive solution, creates little or no toxic effects in a host to which the inventive solution is administered.
- the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids.
- the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methiorine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine.
- the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid.
- the citric acid comprises dibasic citrate.
- Citrate a key constituent of the metabolic system, is aggressively drawn to the cells throughout the body and provides an efficient delivery system for spreading the silver through the body before decomplexing takes place and the silver is gradually released as available free silver ions.
- acetic acid certain crown ethers
- primary, secondary or tertiary amines such as ethanolamine
- substantially non-toxic, substantially thiol-free, substantially watersoluble complexing agents are also useful.
- the inventive substantially non-colloidal solution possesses greater than about twenty parts of silver per million parts of the non-colloidal solution.
- PPM is defined as parts of total silver to 1,000,000 parts of the total solution including the water base and all substances contained in it by weight.
- the substantially non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution.
- the substantially non-colloidal solution posesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution. Higher parts per million of total silver are desirable, as biological effectiveness increases as PPM free silver increases.
- 100 PPM of silver is a desirable level for the total concentration of silver because it provides a highly effective concentration of silver yet the concentration is low enough to facilitate ease of measuring and dispensing the small dosages appropriate for small children and small animals.
- the amount of silver can vary substantially, within solubility limits, without departing from the scope of the invention, as long as the other elements are varied in relative proportion to the silver.
- the inventive solution may be comprised of as little as about 10 PPM of silver or as much as about 10,000 PPM of silver without departing from the scope of the invention.
- counter ions may be utilized. Such counter ions may be used to balance the charge present in the recited complexing agent, if necessary.
- Sources for counter ions suitable for use in this invention include those conventionally known sources of counter ions. Any suitable source of counter ions may be used where the complexing agent is such that a counter ion is required to maintain the electrical stability of the silver complex, so long as the counter ion used does not compete with the silver for the complexing agent.
- the source of counter-ions comprises potassium ions, or calcium ions.
- the inventive non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one-tenth of a weight percent of free silver based on the weight of total silver.
- a relatively low amount of free silver as compared to total silver (including non-free silver or complexed silver) is retained in a non-reacted state in the inventive solution, until released over time by the equilibrium driving force. This controlled release aspect of the inventive formulation is desirable, as activity is retained over time.
- the preferred embodiment of the invention containing a complex of citrate and silver with potassium as a counter ion, may include the following complex of ions in a solution of relatively pure water:
- the inventive solution may be made by mixing silver oxide, citric acid and tripotassium citrate in an approximately 1*4 molar ratio, respectively, in sufficient pure water to produce a silver concentration of 100 parts per million.
- Other formulations which result in an approximate 1:2 molar ratio to an approximate 1:20 molar ratio of silver to dibasic citrate in no way depart from the scope of the invention.
- a preferable molar ratio (as dry ingredient or as solution) of silver to complexing agent is from about 1:1 to about 1:200, more preferably from about 1:1.5 to 1:50, most preferably from about 1:2 to about 1:20.
- the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount.
- the inventors have also produced the product following the general procedures described above but reducing the amounts of citric acid and of potassium citrate to half of the amounts described above. Numerous other variations can also be utilized with these starting ingredients provided that the ratio of citric acid to potassium citrate is generally maintained. Likewise, the amount of silver oxide may be substantially increased or decreased provided that a reasonably commensurate adjustment is made in the relative amounts of citric acid and of potassium citrate to silver oxide although, as demonstrated by the fact that the product was successfully produced upon changing the ratio of silver oxide to citric acid and to potassium citrate by 100 %, substantial latitude exists with regard to that ratio.
- ionic silver can kill over 650 disease-causing germs.
- the invention is absolutely harmless to the body when used in the low quantities needed for the antimicrobial action to occur, especially since the formulation provides an efficiently controlled, gradual release of free silver ions (provided that the complexing agent is nontoxic), requiring less silver ingestion in order to obtain the benefits of silver ion activity that other substances cannot render with substantially higher levels of silver ingestion.
- Ionic silver is used for literally hundreds of conditions, including eye and ear infections, nose, sinus and gum infections, acne, sore throats, colds and flu, candida, bladder and vaginal infections, cuts and bums, many skin conditions, bug bites, fighting nail and skin fungus, healing sunburn, alleviating diaper rash and bed sores, providing a soothing skin treatment after shaving, and use as a mouth rinse.
- Body odors are caused by bacteria in the perspiration, which is often alleviated upon application of the invention, clearly demonstrating how effectively it kills bacteria.
- Ionic silver is also used for treating ulcers, both in fighting the bacteria that can aggravate an ulcer and in repairing the damaged stomach lining.
- Ionic silver is used for many severe conditions as well, including, for example, tuberculosis, Epstein-Barr Virus, Lyme Disease, Legionnaires' Disease, bronchitis, chicken pox, and numerous others. There are actually few germ-related conditions, or conditions requiring the repair of tissue, for which ionic silver is not used, since many claim it is not only effective in killing most bacteria but also many if not most fungus and viruses. Some reports indicate that it is also effective against a number of parasites that might invade the body. Ionic silver is also reported by some researchers to be effective at treating cancer and HIV.
- Ionic silver is also considered by many to be very useful in oral irrigation systems designed for consumer use, that spray a fine stream of water in the mouth, in fighting infection and healing gums. Ionic silver is even reputed to be quite effective in facilitating the growth of hair in the local area on which it is topically applied.
- the product can readily be bottled or packaged with a variety of types of dispensers to further facilitate its usefulness.
- a bottle with a dropper is most convenient for eye drops, ear drops and nose drops.
- a plastic squeeze bottle can serve as a convenient dispenser for eye drops and ear drops, while the same with a nasal sprayer feature can readily facilitate use as a sinus and nasal spray.
- a spray dispenser such as with, for instance, a pump spray, makes it very convenient to apply the product externally and also provides a convenient and efficient method for oral use and internal ingestion. By disbursing the product upon spraying it in the mouth, such a spray facilitates absorption of the formula into the blood system through the tissue lining in the mouth.
- a spray dispenser also facilitates delivery of the product to the lungs as one may inhale while spraying the product towards the throat area. while inhaling. Because of the existence of a weak complex of silver and the existence of available free silver ions, along with the photoreactive qualities of silver, packaging should preferably be in an opaque glass container, in a stainless steel container, or in a polypropylene or polyethylene plastic container. Ideally, dispensers should be made of such materials as well.
- the product can be used for humans as well as animals.
- the complexing agent is a nontoxic material
- the product is safe for children and pets.
- the invention has a wide range of potential uses for both medical and veterinary applications.
- the product can also be applied to surfaces for killing germs thereon. For instance, it can be sprayed on counter tops, cutting boards, toilet seats, doorknobs, telephone handsets, etc. Upon contact with germ cells, the available free silver ions should react with and kill the germ cell, causing another silver ion to be decomplexed and released from the complexing agent and be made available.
- the invention may be utilized in both the prevention and the treatment of disease.
- an individual may ingest the product on a daily basis as a preventative, achieving substantial levels of protection from germs, while remaining within extremely safe limits of daily and lifelong silver intake relative to the amount of silver contained in the product in the preferred embodiment.
- an individual consuming a substantial amount of the product on a daily basis in terms of potential health benefits would, in fact, be consuming no more silver than that amount which was depleted from the diets over that period of time.
- stir speed was turned to high and stirring continued for approximately an additional 30 minutes, filling the carboy to approximately the 18-liter mark, turning off the stirrer, opening the water input valve and stopping the water input at precisely the 19-liter mark, turning the stirrer back on to the high speed, and stirring for an additional 60 minutes.
- Example 1 A 31-year old male and a 28-year old male who work together in the same store had both come down with a full-blown flu. Both took fifteen drops of the solution of Example 1 in an oral dose, one time, and within a day-and-a-half both were completely free of any further symptoms.
- a one-year old male was diagnosed with a blocked tear duct in his left eye. Every day, he awoke with a green drainage that continued through the day. Two physicians recommended surgery. The boys mother administered only one drop of the solution of Example 1 in his eye each day for two days. The condition disappeared. Upon a follow-up nine months later, the condition had not returned.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Colloid Chemistry (AREA)
Abstract
The invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
Description
- This application claims priority to U.S. Provisional Patent Application No. 60/107710, filed Nov. 9, 1998.
- 1. Field of the Invention
- This invention relates to solutions including complexed ionic silver. More particularly, it relates to solutions including complexed ionic silver wherein the solutions convey health benefits through their use or application.
- 2. Description of Related Art
- Silver has been known to act antimicrobially as an agent in and on the body of humans as well as other animals, and to be relatively non-toxic to mammalian cells when used in the minute quantities needed to be antimicrobially effective. The most effective form of silver for antimicrobial use is as ions in solution. Silver ions have been shown in the past to have antibacterial, antiviral and antifungal qualities, and to contribute directly to the regeneration of tissue. While the exact method by which silver ions perform these functions is not known, it is believed that they may (1) disrupt the respiratory functions, or (2) disrupt membrane functionality of single-celled microorganisms, or (3) link to the cell's DNA and disrupt cell functions. It is not conventionally understood why silver ions appear to some to be effective at regenerating tissue, which apparently involves more than acting as an antimicrobial agent.
- During recent years, ionic silver substances have been undergoing a substantial resurgence in popularity, and are increasingly regarded as a reasonably safe and effective antimicrobial agent. Silver ion substances are increasingly being used in medical applications as well as by those seeking a natural alternative to traditional antibiotic medications. Ionic silver substances are being used in topical dressings to treat wounds and to prevent and treat infections. They are also being used for water supply sanitation for public utilities, for pharmaceutical equipment sanitation, and for killing germs including the germ that causes Legionnaires' Disease in the water systems of hospitals. Tooth brushes are now being introduced that release silver ions in order to fight oral bacteria.
- However, delivering silver ions for utilization in or on the body is a challenge because silver ions are electrically attracted to a host of substances in and on the body, resulting in the silver ions rapidly forming complexes or compounds wherein the ion is no longer available to perform the appropriate antimicrobial function. A controlled, gradual release of silver ions is desirable for achieving appropriate use of silver ions in or on the body in order to offset this phenomenon, and is especially challenging for antimicrobial use of silver ions internally such as upon oral ingestion. If free silver, defined as silver ions which are not part of a complex or compound, and are therefore biologically available, are delivered at once to the body, there is only opportunity for them to perform the antimicrobial function for an instant where they make contact with the body or the oral tissue before being rendered inactive.
- The desirable characteristics of an antimicrobial ionic silver formulation are that it gradually releases its silver content as free silver ions upon ingestion or upon topical application in a manner that is slow enough to sustain the antimicrobial functionality for a sufficient period of time while also being rapid enough to be substantially effective, that it facilitate mobility of the silver through the body upon oral ingestion prior to gradually releasing its silver content as available free silver ions, and that it be nontoxic to the body.
- Topical applications of ionic silver do not require a controlled, gradual release of silver ions to the degree that internal, oral ingestion applications require it because there is a lower presence of agents with which the silver ions can bind up and form complexes or compounds upon topical exposure as compared with ingestion for internal use. At least one product has been recently introduced that consists of a film dressing impregnated with a complex that gradually releases silver ions upon exposure to the body's chemistry.
- Previously, some silver-containing chemical substances, such as silver nitrate, have been utilized in an effort to gain the antimicrobial benefits of silver ions, but these substances have proven minimally effective in or on the body because they immediately deliver all of their silver content as free silver ions. Some such substances, such as silver nitrate, are undesirably toxic to the human body when administered in typical doses.
- Colloidal silver is a substance which has been in use for about a hundred years. It provides a reasonable degree of controlled release and mobility of silver ions in and on the body. Colloidal silver is apparently made up of minute particles of silver, associated with silver ions that comprise a small percentage of such particles. The mass of these particles provide a degree of controlled, gradual release of silver ions as the body's chemistry breaks down these particles.
- However, the electrolysis process that is used to make most colloidal silver has substantial limitations and does not enable adequate consistency in terms of parts per million (PPM) of silver relative to the total solution by molar weight, particle size, or percentage of ions, for most desired applications. Additionally, purity of the substance is typically limited because electrolytes must usually be added to the water during the production method, the most common of which is sodium. Oxides typically form during production, often resulting in an undesirable yellow or brown color. Moreover, the potency of most electrically produced colloidal silver is inherently limited. After a concentration of approximately 5 PPM of silver (in some cases up to approximately 20 PPM of silver) is reached, the production method typically fails to continue yielding electron-deficient silver particles. The particles formed after such a concentration is reached are typically not capable of performing antimicrobial functions as do the particles that are initially produced prior to reaching this approximate level of total silver concentration (the aggregate of the complexed silver and the free, available silver in the water-based solution).
- The term colloidal means “something suspended in a dissimilar medium,” and shelf life is, therefore, inherently limited because the colloidal silver particles gradually settle out of the water. Colloidal particles are not dissolved in the water medium; they are not in solution. The suspension is a result of, for example, Brownian motion which is insufficient to keep the particles from settling out over time. Some colloidal silver substances have stabilizing agents such as proteins added to the formula, but these tend to further hinder the availability of the silver ions to the body. What is therefore needed are compositions comprising silver ions, and methods of making and using such compositions, that address the aforementioned problems.
- In an aspect, the invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
- The inventors have unexpectedly discovered that a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent overcomes many of the limitations inherent in the aforementioned forms of ionic silver substances and has wide application in and on the body.
- The inventive, substantially non-colloidal solution provides silver ion concentrations well above those typically provided by colloidal silver products. The production method provides a typically consistent formulation. The inventive formulation is highly stable, has many years of shelf life, and maintains its consistency and structure under a wide range of environmental conditions. Substantially wide concentration ranges of complexed silver are attainable without significantly compromising the desirable characteristics of the product. The composition of the invention efficiently provides for substantial mobility of the silver complex through the body and for controlled decomplexing of its silver content, whereupon it gradually releases silver as available free silver ions, upon introduction of the product to the body's chemistry internally through oral ingestion or upon topical application.
- Further, the inventive, substantially non-colloidal solution is relatively nontoxic to the human body at typical doses.
- The inventive substantially non-colloidal solutions are made from ingredients comprising water, a source of free silver ions; and a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
- Water usable in the practice of this invention should be relatively pure. Suitable types of water include: deionized water, distilled water, reverse osmosis filtered water, reagent grade water and USP grade water suitable for use in pharmaceuticals. The water is desirably substantially free of contaminants, such as parasites, pathogens, chemical contaminants, and particulate contamination.
- The source of silver ions may be virtually any compound or complex which includes silver ions as a constituent, from which those silver ions can be obtained in order to be complexed with the recited complexing agent or to become free silver ions as part of the inventive solution. Sources of silver ions comprise silver oxide, trisilver citrate, silver acetate, water soluble silver salts or any number of other sources of silver without departing from the scope of the invention. In a preferable embodiment, the source of silver ions is silver oxide (AgO). On complexing, silver oxide eliminates a superfluous counter ion, hydroxide, which is innocuous since hydroxide is already present in the solution.
- The substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent serves primarily to provide a “controlled release” of biologically active silver ions. In the context of the invention, complexing agent may be taken to mean an ionic material with which silver ions are complexed in such a manner that the complexing agent forms a weak bond with the silver ions wherein the missing electron position which is a characteristic of the silver ion is filled by an electron of the complexing agent. The substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent may comprise a carboxylic acid, or a primary, secondary or tertiary amine. In the context of this invention, substantially non-toxic may be taken to mean that the recited complexing agent, when present in the inventive solution in usual amounts according to the invention, and when administered as part of the inventive solution in usual dosage amounts of the inventive solution, creates little or no toxic effects in a host to which the inventive solution is administered. In an embodiment, the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids. In a preferable embodiment, the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methiorine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine. In another preferable embodiment, the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid. In a more preferable embodiment, the citric acid comprises dibasic citrate. Citrate, a key constituent of the metabolic system, is aggressively drawn to the cells throughout the body and provides an efficient delivery system for spreading the silver through the body before decomplexing takes place and the silver is gradually released as available free silver ions. Also useful are acetic acid; certain crown ethers; primary, secondary or tertiary amines, such as ethanolamine, and other conventionally known substantially non-toxic, substantially thiol-free, substantially watersoluble complexing agents.
- In an embodiment, the inventive substantially non-colloidal solution possesses greater than about twenty parts of silver per million parts of the non-colloidal solution. In the context of this invention, PPM is defined as parts of total silver to 1,000,000 parts of the total solution including the water base and all substances contained in it by weight. In another embodiment, the substantially non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution. In a more preferable embodiment, the substantially non-colloidal solution posesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution. Higher parts per million of total silver are desirable, as biological effectiveness increases as PPM free silver increases.
- 100 PPM of silver is a desirable level for the total concentration of silver because it provides a highly effective concentration of silver yet the concentration is low enough to facilitate ease of measuring and dispensing the small dosages appropriate for small children and small animals. However, the amount of silver can vary substantially, within solubility limits, without departing from the scope of the invention, as long as the other elements are varied in relative proportion to the silver. In another embodiment, the inventive solution may be comprised of as little as about 10 PPM of silver or as much as about 10,000 PPM of silver without departing from the scope of the invention.
- In an aspect of the invention, counter ions may be utilized. Such counter ions may be used to balance the charge present in the recited complexing agent, if necessary. Sources for counter ions suitable for use in this invention include those conventionally known sources of counter ions. Any suitable source of counter ions may be used where the complexing agent is such that a counter ion is required to maintain the electrical stability of the silver complex, so long as the counter ion used does not compete with the silver for the complexing agent. In a preferable embodiment, the source of counter-ions comprises potassium ions, or calcium ions.
- In an aspect of the invention, the inventive non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one weight percent of free silver based on the weight of total silver. In an aspect of the invention, the non-colloidal solution possesses less than about one-tenth of a weight percent of free silver based on the weight of total silver. A relatively low amount of free silver as compared to total silver (including non-free silver or complexed silver), is retained in a non-reacted state in the inventive solution, until released over time by the equilibrium driving force. This controlled release aspect of the inventive formulation is desirable, as activity is retained over time.
- The preferred embodiment of the invention, containing a complex of citrate and silver with potassium as a counter ion, may include the following complex of ions in a solution of relatively pure water:
- In a preferable embodiment the inventive solution may be made by mixing silver oxide, citric acid and tripotassium citrate in an approximately 1*4 molar ratio, respectively, in sufficient pure water to produce a silver concentration of 100 parts per million. Other formulations which result in an approximate 1:2 molar ratio to an approximate 1:20 molar ratio of silver to dibasic citrate in no way depart from the scope of the invention. Generally, a preferable molar ratio (as dry ingredient or as solution) of silver to complexing agent is from about 1:1 to about 1:200, more preferably from about 1:1.5 to 1:50, most preferably from about 1:2 to about 1:20.
- In another preferable embodiment, the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount.
- The inventors have also produced the product following the general procedures described above but reducing the amounts of citric acid and of potassium citrate to half of the amounts described above. Numerous other variations can also be utilized with these starting ingredients provided that the ratio of citric acid to potassium citrate is generally maintained. Likewise, the amount of silver oxide may be substantially increased or decreased provided that a reasonably commensurate adjustment is made in the relative amounts of citric acid and of potassium citrate to silver oxide although, as demonstrated by the fact that the product was successfully produced upon changing the ratio of silver oxide to citric acid and to potassium citrate by 100%, substantial latitude exists with regard to that ratio.
- As previously stated herein, numerous alternative source ingredients for yielding the silver ion, complexing agent, and counter ion for the preferred embodiment of the invention may also be used, requiring appropriately adjusted quantities, and, likewise, numerous other complexing agents and, if required, counter ion agents, may be selected as the constituents of the product as well, also requiring the appropriately adjusted quantities of the appropriate source ingredients necessary to produce the desired product.
- It has often been claimed that ionic silver can kill over 650 disease-causing germs. The invention is absolutely harmless to the body when used in the low quantities needed for the antimicrobial action to occur, especially since the formulation provides an efficiently controlled, gradual release of free silver ions (provided that the complexing agent is nontoxic), requiring less silver ingestion in order to obtain the benefits of silver ion activity that other substances cannot render with substantially higher levels of silver ingestion.
- Ionic silver is used for literally hundreds of conditions, including eye and ear infections, nose, sinus and gum infections, acne, sore throats, colds and flu, candida, bladder and vaginal infections, cuts and bums, many skin conditions, bug bites, fighting nail and skin fungus, healing sunburn, alleviating diaper rash and bed sores, providing a soothing skin treatment after shaving, and use as a mouth rinse. Body odors are caused by bacteria in the perspiration, which is often alleviated upon application of the invention, clearly demonstrating how effectively it kills bacteria. Ionic silver is also used for treating ulcers, both in fighting the bacteria that can aggravate an ulcer and in repairing the damaged stomach lining. Ionic silver is used for many severe conditions as well, including, for example, tuberculosis, Epstein-Barr Virus, Lyme Disease, Legionnaires' Disease, bronchitis, chicken pox, and numerous others. There are actually few germ-related conditions, or conditions requiring the repair of tissue, for which ionic silver is not used, since many claim it is not only effective in killing most bacteria but also many if not most fungus and viruses. Some reports indicate that it is also effective against a number of parasites that might invade the body. Ionic silver is also reported by some researchers to be effective at treating cancer and HIV.
- Other uses for ionic silver range from purifying bottled water by placing some in the water, to retardation of food spoilage at home. Recent studies show that over 30 percent of bottled water contains bacteria levels above safety limits, which can readily be addressed with a few drops of the invention being added to the water. Spraying sliced fruits with the formulation of the invention can keep them fresh up to a week before spoilage, clearly demonstrating how effectively the invention kills bacteria on foods. It is also used to reverse existing contamination of foods.
- Ionic silver is also considered by many to be very useful in oral irrigation systems designed for consumer use, that spray a fine stream of water in the mouth, in fighting infection and healing gums. Ionic silver is even reputed to be quite effective in facilitating the growth of hair in the local area on which it is topically applied.
- In virtually all applications for which ionic silver is used, the advantages of a relatively high PPM of silver, a controlled, gradual release of available free silver ions and, in the case of the preferred embodiment of the invention, the benefit of citrate as a carrier on internal use together with the lack of toxicity and minimum likelihood of incurring mutated strains of germs, all serve to provide substantially superior benefits to those who would use the product for any of the myriad of conditions for which ionic silver would be used.
- The product can readily be bottled or packaged with a variety of types of dispensers to further facilitate its usefulness. A bottle with a dropper is most convenient for eye drops, ear drops and nose drops. Alternatively, a plastic squeeze bottle can serve as a convenient dispenser for eye drops and ear drops, while the same with a nasal sprayer feature can readily facilitate use as a sinus and nasal spray. A spray dispenser such as with, for instance, a pump spray, makes it very convenient to apply the product externally and also provides a convenient and efficient method for oral use and internal ingestion. By disbursing the product upon spraying it in the mouth, such a spray facilitates absorption of the formula into the blood system through the tissue lining in the mouth. A spray dispenser also facilitates delivery of the product to the lungs as one may inhale while spraying the product towards the throat area. while inhaling. Because of the existence of a weak complex of silver and the existence of available free silver ions, along with the photoreactive qualities of silver, packaging should preferably be in an opaque glass container, in a stainless steel container, or in a polypropylene or polyethylene plastic container. Ideally, dispensers should be made of such materials as well.
- Topically applying a gauze, cotton, sheer strip or other type of bandage or fabric that has been saturated with the product is another alternative for using the product.
- The product can be used for humans as well as animals. When the complexing agent is a nontoxic material, the product is safe for children and pets. Thus, the invention has a wide range of potential uses for both medical and veterinary applications.
- The product can also be applied to surfaces for killing germs thereon. For instance, it can be sprayed on counter tops, cutting boards, toilet seats, doorknobs, telephone handsets, etc. Upon contact with germ cells, the available free silver ions should react with and kill the germ cell, causing another silver ion to be decomplexed and released from the complexing agent and be made available.
- The invention may be utilized in both the prevention and the treatment of disease.
- Due to the efficient delivery of silver ions afforded by the invention, an individual may ingest the product on a daily basis as a preventative, achieving substantial levels of protection from germs, while remaining within extremely safe limits of daily and lifelong silver intake relative to the amount of silver contained in the product in the preferred embodiment. Studies show that the amount of silver in the average daily diet of adult Americans was depleted by as much as 85% between the early half of the 20th century and the latter part of that century. With the preferred embodiment of the invention, an individual consuming a substantial amount of the product on a daily basis in terms of potential health benefits would, in fact, be consuming no more silver than that amount which was depleted from the diets over that period of time.
- Two and one-half liters of pure water were placed in a 5-gallon (1 9-liter functional capacity) carboy mounted on a magnetic stirrer with a Teflon-coated magnetic stir bar placed inside the carboy, turning on the stirrer at low speed, adding 6.7675 grams of citric acid anhydrous powder (reagent grade), 11.43 grams of potassium citrate monohydrate crystal (reagent grade), and 2.2450 grams of silver oxide powder (reagent grade), stirring at low speed for approximately 45 minutes. Next more water was slowly fed while continuing to stir at low speed for approximately an additional 15 minutes and stopping the water input when the level reaches approximately 8-9 liters. Then, the stir speed was turned to high and stirring continued for approximately an additional 30 minutes, filling the carboy to approximately the 18-liter mark, turning off the stirrer, opening the water input valve and stopping the water input at precisely the 19-liter mark, turning the stirrer back on to the high speed, and stirring for an additional 60 minutes.
- A 65-year old male developed conjunctivitis and obtained relief within less than five hours upon administering two drops of the solution of Example 1 in his eye.
- A sixteen-year old female had been suffering with acne for three or four years. A dermatologist had been treating her regularly to no avail. She applied six sprays of the solution of Example 1 three times per day to her face for three days and stopped using products from the dermatologist, and by the end of the third day the skin on her face cleared up almost completely. There was no dryness or redness any more.
- A 45-year old male had been diagnosed with lymphatic cancer and after taking an oral dose of one teaspoon of the solution of Example 1 per day for two months, tests showed that not a trace of the disease remained.
- A 31-year old male and a 28-year old male who work together in the same store had both come down with a full-blown flu. Both took fifteen drops of the solution of Example 1 in an oral dose, one time, and within a day-and-a-half both were completely free of any further symptoms.
- A one-year old male was diagnosed with a blocked tear duct in his left eye. Every day, he awoke with a green drainage that continued through the day. Two physicians recommended surgery. The boys mother administered only one drop of the solution of Example 1 in his eye each day for two days. The condition disappeared. Upon a follow-up nine months later, the condition had not returned.
- A 53-year old woman burned the back of her hand on a 450-degree oven. The burn was approximately an inch-and-a-quarter in diameter. After a week, it still had not begun to heal. The pain was still so bad that she could barely move her hand. She put two drops of the solution of Example 1 on it. By that same night, it had completely scabbed over and the entire circumference of the burn had already generated new tissue. The pain was completely gone and she had regained complete movement of her hand. Within about four more days of applying the invention, it was completely healed, without any scarring.
- A 61-year old male had developed a urinary tract infection. A urologist put him on sulfa drugs for twenty days. He suffered through a week of constant nausea, at which point he threw out the remaining pills. He then began to ingest 30 drops of the solution of Example 1 per day, and after three days the infection was no longer detectable.
- A forty-four-year old male developed abscesses surrounding two wisdom teeth. Three oral surgeons told him the teeth had to come out. He applied approximately one teaspoon of the solution of Example 1 each to each of the two affected areas. By the next day, the infections were undetectable and the pain was gone. A follow-up eleven months later showed that it had not returned.
- A twenty-four-year old woman developed a vaginal infection. The doctor's prescription didn't help after almost two weeks. She then mixed one half-teaspoon of the solution of Example 1 in pure water and used the mixture as a douche, and the discomfort disappeared almost immediately and had not returned upon a follow-up three weeks later.
Claims (17)
1. A substantially non-colloidal solution made by combining ingredients comprising:
(a) water;
(b) a source of free silver ions; and
(c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
2. The substantially non-colloidal solution of claim 1 , wherein the non-colloidal solution possesses less than about ten weight percent of free silver based on the weight of total silver.
3. The substantially non-colloidal solution of claim 2 , wherein the non-colloidal solution possesses less than about one weight percent of free silver based the weight of total silver.
4. The substantially non-colloidal solution of claim 3 , wherein the non-colloidal solution possesses less than about one-tenth of a percent by weight of free silver based on the weight of total silver.
5. The substantially non-colloidal solution of claim 1 , wherein the non-colloidal solution possesses greater than about twenty parts of total silver per million parts of the non-colloidal solution.
6. The substantially non-colloidal solution of claim 5 , wherein the non-colloidal solution possesses greater than about fifty parts of total silver per million parts of the non-colloidal solution.
7. The substantially non-colloidal solution of claim 6 , wherein the non-colloidal solution possesses greater than or equal to about one hundred parts of total silver per million parts of the non-colloidal solution.
8. The substantially non-colloidal solution of claim 1 , wherein the source of free silver ions comprises silver oxide, trisilver citrate, or silver acetate.
9. The substantially non-colloidal solution of claim 8 , wherein the source of free silver ions comprises silver oxide.
10. The substantially non-colloidal solution of claim 1 , wherein the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises a carboxylic acid, or a primary, secondary or tertiary amine.
11. The substantially non-colloidal solution of claim 10 , wherein the substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent comprises amino acids or hydroxy acids.
12. The substantially non-colloidal solution of claim 11 , wherein the amino acids comprise glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, or histidine.
13. The substantially non-colloidal solution of claim 12 , wherein the hydroxy acids comprise glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, or mandelic acid.
14. The substantially non-colloidal solution of claim 13 , wherein the citric acid is dibasic citrate.
15. The substantially non-colloidal solution of claim 1 , wherein the free silver ions are present in the substantially non-colloidal solution in an anti-microbially effective amount.
16. The substantially non-colloidal solution of claim 1 , wherein the ingredients further comprise a source of counter-ions.
17. The substantially non-colloidal solution of claim 1 , wherein the source of counter-ions comprises potassium ions, or calcium ions.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/796,242 US20020025344A1 (en) | 1998-11-09 | 2001-02-28 | Ionic silver complex |
| US10/175,260 US20020150628A1 (en) | 1998-11-09 | 2002-06-18 | Ionic silver complex |
| US10/383,345 US6838095B2 (en) | 1998-11-09 | 2003-03-07 | Ionic silver complex |
| US11/028,840 US20050118281A1 (en) | 1998-11-09 | 2005-01-04 | Ionic silver complex |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10771098P | 1998-11-09 | 1998-11-09 | |
| US43515899A | 1999-11-05 | 1999-11-05 | |
| US09/796,242 US20020025344A1 (en) | 1998-11-09 | 2001-02-28 | Ionic silver complex |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US43515899A Continuation | 1998-11-09 | 1999-11-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/175,260 Continuation US20020150628A1 (en) | 1998-11-09 | 2002-06-18 | Ionic silver complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020025344A1 true US20020025344A1 (en) | 2002-02-28 |
Family
ID=22318046
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/796,242 Abandoned US20020025344A1 (en) | 1998-11-09 | 2001-02-28 | Ionic silver complex |
| US10/175,260 Abandoned US20020150628A1 (en) | 1998-11-09 | 2002-06-18 | Ionic silver complex |
| US10/383,345 Expired - Lifetime US6838095B2 (en) | 1998-11-09 | 2003-03-07 | Ionic silver complex |
| US11/028,840 Abandoned US20050118281A1 (en) | 1998-11-09 | 2005-01-04 | Ionic silver complex |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/175,260 Abandoned US20020150628A1 (en) | 1998-11-09 | 2002-06-18 | Ionic silver complex |
| US10/383,345 Expired - Lifetime US6838095B2 (en) | 1998-11-09 | 2003-03-07 | Ionic silver complex |
| US11/028,840 Abandoned US20050118281A1 (en) | 1998-11-09 | 2005-01-04 | Ionic silver complex |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20020025344A1 (en) |
| EP (1) | EP1128824A1 (en) |
| JP (2) | JP2002529411A (en) |
| AU (1) | AU776212B2 (en) |
| BR (1) | BR9915174A (en) |
| NZ (1) | NZ512267A (en) |
| WO (1) | WO2000027390A1 (en) |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020192298A1 (en) * | 2001-04-23 | 2002-12-19 | Burrell Robert Edward | Treatment of acne |
| US20030180378A1 (en) * | 2000-07-27 | 2003-09-25 | Gillis Scott H. | Dry powders of metal-containing compounds |
| US20030203046A1 (en) * | 2000-07-27 | 2003-10-30 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
| US20030206966A1 (en) * | 2000-07-27 | 2003-11-06 | Burrell Robert E. | Methods of inducing apoptosis and modulating metalloproteinases |
| US6692773B2 (en) | 2000-07-27 | 2004-02-17 | Nucryst Pharmaceuticals Corp. | Treatment of hyperproliferative skin disorders and diseases |
| US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| US6723350B2 (en) | 2001-04-23 | 2004-04-20 | Nucryst Pharmaceuticals Corp. | Lubricious coatings for substrates |
| US20040110738A1 (en) * | 2002-10-22 | 2004-06-10 | Gillis Scott H. | Prophylactic treatment methods |
| US20040131698A1 (en) * | 2000-07-27 | 2004-07-08 | Gillis Scott H. | Methods of treating conditions using metal-containing materials |
| US20040129112A1 (en) * | 2000-07-27 | 2004-07-08 | Gillis Scott H. | Metal-containing materials |
| US20040176312A1 (en) * | 2002-04-23 | 2004-09-09 | Gillis Scott H. | Treatment of ungual and subungual diseases |
| US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
| US20050089539A1 (en) * | 2003-09-09 | 2005-04-28 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| US20060052452A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US20060051385A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US20060263444A1 (en) * | 2005-05-19 | 2006-11-23 | Xintian Ming | Antimicrobial composition |
| US20080014247A1 (en) * | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| US20080229929A1 (en) * | 2007-03-22 | 2008-09-25 | Ken Marcoon | Antimicrobial filtration article |
| US20080287538A1 (en) * | 2005-03-10 | 2008-11-20 | Scholz Matthew T | Antimicrobial Compositions and Methods |
| US20080292722A1 (en) * | 2007-05-18 | 2008-11-27 | Crudden Joseph J | Food preservation compositions and methods |
| US7470437B2 (en) | 2000-07-27 | 2008-12-30 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions with a metal-containing material |
| US20090005339A1 (en) * | 2005-03-10 | 2009-01-01 | Scholz Matthew T | Methods of Treating Ear Infections |
| US20090010981A1 (en) * | 2000-08-31 | 2009-01-08 | Bio-Gate Ag | Antimicrobial material for implanting in bones |
| US20090162448A1 (en) * | 2007-12-20 | 2009-06-25 | Nucryst Pharmaceuticals Corp. | Metal Carbonate Particles and Methods of Making Thereof |
| US20090226541A1 (en) * | 2005-03-10 | 2009-09-10 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| US9295254B2 (en) | 2011-12-08 | 2016-03-29 | Sciessent Llc | Nematicides |
| CN114766520A (en) * | 2022-05-20 | 2022-07-22 | 千藤(南京)环保科技有限公司 | Citric acid three-silver composition, preparation method and application |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1428A (en) * | 1997-10-10 | 2005-06-08 | Nvid Int Inc | Disinfectant and method of making. |
| NZ512267A (en) * | 1998-11-09 | 2003-11-28 | Ira Jay Newman | Ionic silver complex |
| US7261905B2 (en) * | 1999-04-07 | 2007-08-28 | Pure Bioscience | Disinfectant and method of making |
| US6242009B1 (en) * | 1999-04-20 | 2001-06-05 | Kareem I. Batarseh | Microbicidal formulations and methods to control microorganisms |
| US6890953B2 (en) * | 2000-04-06 | 2005-05-10 | Innovative Medical Services | Process for treating water |
| US6630172B2 (en) | 2001-01-22 | 2003-10-07 | Kareem I. Batarseh | Microbicidal composition containing potassium sodium tartrate |
| US20040044073A1 (en) * | 2002-08-31 | 2004-03-04 | Innovative Medical Services | Composition and process for treating acne |
| US7435438B1 (en) | 2003-05-16 | 2008-10-14 | Pure Bioscience | Disinfectant and method of use |
| DK200301128A (en) * | 2003-08-05 | 2005-02-06 | Thomsen Joern Oddershede | Grant Preparation |
| EP1675463A4 (en) * | 2003-08-28 | 2010-09-29 | Pure Bioscience | Anhydrous silver dihydrogen citrate compositions |
| SE528045C2 (en) * | 2004-02-23 | 2006-08-15 | Polygiene Ab | Use of a plastic composition to provide a surface with antivirus activity |
| JP5586816B2 (en) | 2004-03-15 | 2014-09-10 | 大正製薬株式会社 | Composition containing zinc compound |
| EP1755624A4 (en) * | 2004-05-03 | 2009-04-29 | Neosil Inc | Polycationic antimicrobial therapeutic |
| US20060051430A1 (en) * | 2004-09-07 | 2006-03-09 | Arata Andrew B | Silver dihydrogen citrate compositions |
| US20060115440A1 (en) * | 2004-09-07 | 2006-06-01 | Arata Andrew B | Silver dihydrogen citrate compositions |
| US8048870B2 (en) * | 2005-01-11 | 2011-11-01 | Batarseh Kareem I | Apoptosis-inducing antineoplastic silver (I) coordination complexes |
| US20060216322A1 (en) * | 2005-03-25 | 2006-09-28 | Kenko Corporation | Feed composition and method for breeding animals |
| US20090074881A1 (en) * | 2006-05-02 | 2009-03-19 | Bioneutral Laboratories Corporation Usa | Antimicrobial cidality formulations with residual efficacy, uses thereof, and the preparation thereof |
| EP1938690B1 (en) * | 2006-12-22 | 2013-10-23 | Preentec AG | Sterilising and preserving fluids |
| US9393261B2 (en) * | 2011-07-22 | 2016-07-19 | Body Glide LLC | Antimicrobial anti-chafing chelated silver oxide compound |
| US9132296B2 (en) * | 2007-05-17 | 2015-09-15 | Ag Essence | Antimicrobial solution and methods of making and using the same |
| EP2299827A4 (en) * | 2008-06-06 | 2014-01-08 | Pure Bioscience | Agricultural applications of silver dihydrogen citrate |
| DE102008031927B4 (en) | 2008-07-08 | 2017-09-14 | Beiersdorf Ag | Cosmetic preparations with passivated silver |
| US8399028B2 (en) * | 2008-08-14 | 2013-03-19 | Exciton Technologies Inc. | Antimicrobial silver solutions |
| US8535729B2 (en) * | 2008-12-05 | 2013-09-17 | The Clorox Company | Natural silver disinfectant compositions |
| JP6001906B2 (en) * | 2012-04-04 | 2016-10-05 | 株式会社Powerful Trade Limited Japan | Method for producing bacteriostatic bactericidal deodorant composition for rubble and bacteriostatic bactericidal deodorant composition for rubble |
| WO2014092747A1 (en) * | 2012-12-12 | 2014-06-19 | William Wingfield | Metal oxide complexes and infusion of complexes into polymer compounds |
| US10640403B2 (en) | 2013-08-15 | 2020-05-05 | Applied Silver, Inc. | Antimicrobial batch dilution system |
| US11618696B2 (en) | 2013-08-15 | 2023-04-04 | Applied Silver, Inc. | Antimicrobial batch dilution system |
| US9689106B2 (en) | 2013-12-06 | 2017-06-27 | Applied Silver, Inc. | Antimicrobial fabric application system |
| RU2681544C2 (en) | 2014-01-27 | 2019-03-11 | ЭЙДАНС СКИНКЕАР энд ТОПИКАЛ СОЛЮШЕНС ЛЛК | Topical antibiotic formulations |
| US10808047B2 (en) | 2015-08-21 | 2020-10-20 | G&P Holding, Inc. | Silver and copper itaconates and poly itaconates |
| US20170050870A1 (en) | 2015-08-21 | 2017-02-23 | Applied Silver, Inc. | Systems And Processes For Treating Textiles With An Antimicrobial Agent |
| WO2017067852A1 (en) * | 2015-10-21 | 2017-04-27 | Unilever N.V. | An antimicrobial composition |
| EP3454660B1 (en) | 2016-05-12 | 2022-04-06 | Applied Silver Inc. | Articles and methods for dispensing metal ions into laundry systems |
| WO2018081774A1 (en) | 2016-10-31 | 2018-05-03 | Applied Silver, Inc. | Dispensing of metal ions into batch laundry washers and dryers |
| EP3615092A4 (en) | 2017-03-01 | 2021-03-10 | Applied Silver Inc. | SYSTEMS AND METHODS FOR THE TREATMENT OF TEXTILES WITH AN ANTIMICROBIAL ACTIVE SUBSTANCE |
| EA029076B1 (en) * | 2017-03-22 | 2018-02-28 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | Antimicrobial agent |
| KR102123206B1 (en) * | 2020-02-19 | 2020-06-16 | 곽병상 | Antimicrobial Composition Comprising Silver Compound and Complexing Agent |
| CN111205312B (en) * | 2020-03-31 | 2021-03-16 | 榫卯科技服务(温州)有限公司 | Antibacterial rare earth complex material and preparation method thereof |
| KR102223638B1 (en) * | 2020-07-28 | 2021-03-04 | 곽병상 | PSA stabilizer in blood comprising antimicrobial composition containing silver compound and complexing agent and Panax notoginseng extract |
| WO2022031537A1 (en) * | 2020-08-03 | 2022-02-10 | Reed Frank Joseph | Compositions for prevention and treatment of rsv and coronavirus infection |
| CA3228816A1 (en) * | 2021-08-13 | 2023-02-16 | Onyx Lotus, Llc | Light stable liquid disinfectant compositions |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE400040A (en) * | ||||
| US3826639A (en) * | 1971-02-16 | 1974-07-30 | Basf Ag | Agent for keeping cut flowers fresh |
| NL147015B (en) | 1971-02-16 | 1975-09-15 | Basf Ag | PROCESS FOR THE PREPARATION OF A PREPARATION FOR KEEPING CUT FLOWERS IN FRESH CONDITION. |
| DE2260566A1 (en) * | 1972-12-11 | 1974-06-12 | Christoffers Maschinenfab Gmbh | WIRE DRAWING MACHINE (SCHOTTWAND) |
| FR2399847A1 (en) * | 1977-08-11 | 1979-03-09 | Nat Res Lab | ANTIMICROBIAL AGENTS AND THEIR APPLICATIONS |
| US4055655A (en) | 1975-07-21 | 1977-10-25 | National Research Laboratories | Complexes of heavy metal ions and polyfunctional organic ligands used as antimicrobial agents |
| JPS5437824A (en) * | 1977-08-30 | 1979-03-20 | Nat Risaachi Lab | Bacteriocide comprising metal complex compound |
| CA1218600A (en) * | 1982-12-06 | 1987-03-03 | Gerald L. Maurer | Methods and compositions for treating inflammation or arthritis |
| JPS59126492A (en) * | 1982-12-24 | 1984-07-21 | Fujitsu Ltd | Liquid crystal composition |
| JPH0622540B2 (en) * | 1985-12-18 | 1994-03-30 | 株式会社祥光化学研究所 | Structure with deodorant and antibacterial activity |
| CH673225A5 (en) * | 1986-04-22 | 1990-02-28 | Sanosil Ag | |
| JPH02111709A (en) * | 1988-10-20 | 1990-04-24 | Agency Of Ind Science & Technol | Powdery antibacterial and antimycotic agent and production thereof |
| US5032612A (en) * | 1990-05-25 | 1991-07-16 | Smolko Milan J | Non-smoking aid |
| DE4123292C2 (en) | 1991-07-13 | 1996-01-25 | Hungerbach Chemotechnik Gmbh | Oral hygiene and use of a silver colloid stabilized hydrogen peroxide solution in oral hygiene products |
| CA2119444A1 (en) * | 1991-09-20 | 1993-04-01 | Herbert Marty | Preservative for pharmaceutical products |
| US5322520A (en) | 1992-11-12 | 1994-06-21 | Implemed, Inc. | Iontophoretic structure for medical devices |
| JP3595352B2 (en) * | 1993-02-01 | 2004-12-02 | 株式会社サンギ | Antitumor and antibacterial agents |
| GB9309387D0 (en) * | 1993-05-06 | 1993-06-16 | Wellcome Found | Nitric oxide scavengers |
| US5792793A (en) | 1993-11-05 | 1998-08-11 | Meiji Milk Products Co., Ltd. | Antibacterial, antifungal and antiviral agent |
| CN1090454C (en) | 1994-10-05 | 2002-09-11 | 东陶机器株式会社 | Antibacterial solid, process for producing the same, and method of utilizing the same |
| JPH092926A (en) | 1995-04-12 | 1997-01-07 | Quest Internatl Bv | Stomato-composition |
| JP3449123B2 (en) * | 1996-07-22 | 2003-09-22 | 旭硝子株式会社 | Coating solution for forming low-resistance film or low-refractive-index film, and method for producing low-resistance film or low-reflection low-refractive-index film |
| US5688981A (en) * | 1996-11-21 | 1997-11-18 | Hampshire Chemical Corp. | Ethylenediaminetriacetic acid and N-acyl ethylenediaminetriacetic acid silver chelating agents and surfactants |
| US5785972A (en) | 1997-01-10 | 1998-07-28 | Tyler; Kathleen A. | Colloidal silver, honey, and helichrysum oil antiseptic composition and method of application |
| US5932251A (en) | 1997-04-23 | 1999-08-03 | Kirkpatrick; Carole M. | Hair growth promoter and method of using same |
| NL1005965C2 (en) * | 1997-05-05 | 1998-11-13 | Tevan Chemie B V | Disinfectant formulation. |
| AP1428A (en) | 1997-10-10 | 2005-06-08 | Nvid Int Inc | Disinfectant and method of making. |
| JP2000016905A (en) * | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | Antibacterial-fungal agent and antibacterial-fungal material |
| NZ512267A (en) * | 1998-11-09 | 2003-11-28 | Ira Jay Newman | Ionic silver complex |
| EP1036511A3 (en) | 1999-03-15 | 2001-08-29 | Ralf M. Kern | Method for preservation and composition for use therewith |
-
1999
- 1999-11-05 NZ NZ512267A patent/NZ512267A/en unknown
- 1999-11-05 EP EP99971711A patent/EP1128824A1/en not_active Ceased
- 1999-11-05 WO PCT/US1999/026223 patent/WO2000027390A1/en active IP Right Grant
- 1999-11-05 BR BR9915174-0A patent/BR9915174A/en not_active Application Discontinuation
- 1999-11-05 AU AU14701/00A patent/AU776212B2/en not_active Ceased
- 1999-11-05 JP JP2000580619A patent/JP2002529411A/en active Pending
-
2001
- 2001-02-28 US US09/796,242 patent/US20020025344A1/en not_active Abandoned
-
2002
- 2002-06-18 US US10/175,260 patent/US20020150628A1/en not_active Abandoned
-
2003
- 2003-03-07 US US10/383,345 patent/US6838095B2/en not_active Expired - Lifetime
-
2005
- 2005-01-04 US US11/028,840 patent/US20050118281A1/en not_active Abandoned
-
2011
- 2011-12-16 JP JP2011275453A patent/JP5722757B2/en not_active Expired - Lifetime
Cited By (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US20070010778A1 (en) * | 2000-03-13 | 2007-01-11 | Nucryst Pharmaceuticals Corp., A Canadian Corporation | Transcutaneous medical device dressings and method of use |
| US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| US20040131698A1 (en) * | 2000-07-27 | 2004-07-08 | Gillis Scott H. | Methods of treating conditions using metal-containing materials |
| US7427416B2 (en) | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
| US20030206966A1 (en) * | 2000-07-27 | 2003-11-06 | Burrell Robert E. | Methods of inducing apoptosis and modulating metalloproteinases |
| US6989157B2 (en) | 2000-07-27 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Dry powders of metal-containing compounds |
| US7470437B2 (en) | 2000-07-27 | 2008-12-30 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions with a metal-containing material |
| US7078060B2 (en) | 2000-07-27 | 2006-07-18 | Nucryst Pharmaceuticals Corp. | Solutions and aerosols of metal-containing compounds |
| US20040129112A1 (en) * | 2000-07-27 | 2004-07-08 | Gillis Scott H. | Metal-containing materials |
| US6692773B2 (en) | 2000-07-27 | 2004-02-17 | Nucryst Pharmaceuticals Corp. | Treatment of hyperproliferative skin disorders and diseases |
| US20080014286A1 (en) * | 2000-07-27 | 2008-01-17 | Nucryst Pharmaceuticals Corp., A Canada Corporation | Metal-containing materials |
| US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
| US7255881B2 (en) | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| US20030203046A1 (en) * | 2000-07-27 | 2003-10-30 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
| US20030180378A1 (en) * | 2000-07-27 | 2003-09-25 | Gillis Scott H. | Dry powders of metal-containing compounds |
| US20090010981A1 (en) * | 2000-08-31 | 2009-01-08 | Bio-Gate Ag | Antimicrobial material for implanting in bones |
| US6989156B2 (en) | 2001-04-23 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Therapeutic treatments using the direct application of antimicrobial metal compositions |
| US6939568B2 (en) | 2001-04-23 | 2005-09-06 | Nucryst Pharmaceuticals Corp. | Treatment of inflammatory skin conditions |
| US6723350B2 (en) | 2001-04-23 | 2004-04-20 | Nucryst Pharmaceuticals Corp. | Lubricious coatings for substrates |
| US20040157073A1 (en) * | 2001-04-23 | 2004-08-12 | Nucryst Pharmaceuticals Corp., A Alberta, Canada Corporation | Lubricious coatings for substrates |
| US7008647B2 (en) | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
| US20060083792A1 (en) * | 2001-04-23 | 2006-04-20 | Nucryst Pharmaceuticals Corp. | Therapeutic treatments using the direct application of antimicrobial metal compositions |
| US20060083777A1 (en) * | 2001-04-23 | 2006-04-20 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
| US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| US7087249B2 (en) | 2001-04-23 | 2006-08-08 | Nucryst Pharmaceuticals Corp. | Treatment of mucosal membranes |
| US20060204591A1 (en) * | 2001-04-23 | 2006-09-14 | Nucryst Pharamaceuticals Corp., A Canadian Corporation | Treatment of mucosal membranes |
| US20020192298A1 (en) * | 2001-04-23 | 2002-12-19 | Burrell Robert Edward | Treatment of acne |
| US20040176312A1 (en) * | 2002-04-23 | 2004-09-09 | Gillis Scott H. | Treatment of ungual and subungual diseases |
| US7201925B2 (en) | 2002-04-23 | 2007-04-10 | Nueryst Pharmaceuticals Corp. | Treatment of ungual and subungual diseases |
| US20040110738A1 (en) * | 2002-10-22 | 2004-06-10 | Gillis Scott H. | Prophylactic treatment methods |
| US10471036B2 (en) | 2003-09-09 | 2019-11-12 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US20050089539A1 (en) * | 2003-09-09 | 2005-04-28 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US8512723B2 (en) | 2003-09-09 | 2013-08-20 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US10016501B2 (en) | 2004-09-07 | 2018-07-10 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US20060051385A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US20060052452A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US8198326B2 (en) | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| US8476319B2 (en) | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
| US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| US20090005339A1 (en) * | 2005-03-10 | 2009-01-01 | Scholz Matthew T | Methods of Treating Ear Infections |
| US20080287538A1 (en) * | 2005-03-10 | 2008-11-20 | Scholz Matthew T | Antimicrobial Compositions and Methods |
| US9826770B2 (en) | 2005-03-10 | 2017-11-28 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
| US20090226541A1 (en) * | 2005-03-10 | 2009-09-10 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| US20060263444A1 (en) * | 2005-05-19 | 2006-11-23 | Xintian Ming | Antimicrobial composition |
| US20080050452A1 (en) * | 2006-06-30 | 2008-02-28 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| US20080014247A1 (en) * | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| US20080014278A1 (en) * | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| US20080044491A1 (en) * | 2006-06-30 | 2008-02-21 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| US7520923B2 (en) | 2007-03-22 | 2009-04-21 | Mvp Textiles & Apparel, Inc. | Antimicrobial filtration article |
| US20090232962A1 (en) * | 2007-03-22 | 2009-09-17 | Ken Marcoon | Antimicrobial filtration article |
| US20080229929A1 (en) * | 2007-03-22 | 2008-09-25 | Ken Marcoon | Antimicrobial filtration article |
| US7744681B2 (en) | 2007-03-22 | 2010-06-29 | Mvp Textiles & Apparel, Inc. | Antimicrobial filtration article |
| US8895044B2 (en) * | 2007-05-18 | 2014-11-25 | Sciessent, Llc | Food preservation compositions and methods |
| AU2008254482B2 (en) * | 2007-05-18 | 2013-11-28 | Sciessent, Llc | Bioactive acid agrichemical compositions and use thereof |
| US20130004587A1 (en) * | 2007-05-18 | 2013-01-03 | Sciessent Llc | Bioactive Acid Agrichemical Compositions and Use Thereof |
| US9034393B2 (en) * | 2007-05-18 | 2015-05-19 | Sciessent Llc | Bioactive acid agrichemical compositions and use thereof |
| US20080292721A1 (en) * | 2007-05-18 | 2008-11-27 | Crudden Joseph J | Bioactive acid agrichemical compositrions and use thereof |
| US20090047364A1 (en) * | 2007-05-18 | 2009-02-19 | Crudden Joseph J | Disinfecting methods and compositions |
| US20080292722A1 (en) * | 2007-05-18 | 2008-11-27 | Crudden Joseph J | Food preservation compositions and methods |
| US20080299222A1 (en) * | 2007-05-18 | 2008-12-04 | Crudden Joseph J | Bioactive agrichemical compositions and use thereof |
| US8865227B2 (en) | 2007-12-20 | 2014-10-21 | Smith & Nephew (Overseas) Limited | Metal carbonate particles and methods of making thereof |
| US20090162448A1 (en) * | 2007-12-20 | 2009-06-25 | Nucryst Pharmaceuticals Corp. | Metal Carbonate Particles and Methods of Making Thereof |
| US9295254B2 (en) | 2011-12-08 | 2016-03-29 | Sciessent Llc | Nematicides |
| CN114766520A (en) * | 2022-05-20 | 2022-07-22 | 千藤(南京)环保科技有限公司 | Citric acid three-silver composition, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012107014A (en) | 2012-06-07 |
| WO2000027390A1 (en) | 2000-05-18 |
| US20020150628A1 (en) | 2002-10-17 |
| US20050118281A1 (en) | 2005-06-02 |
| JP5722757B2 (en) | 2015-05-27 |
| JP2002529411A (en) | 2002-09-10 |
| NZ512267A (en) | 2003-11-28 |
| AU776212B2 (en) | 2004-09-02 |
| EP1128824A1 (en) | 2001-09-05 |
| AU1470100A (en) | 2000-05-29 |
| BR9915174A (en) | 2001-11-06 |
| US20030147970A1 (en) | 2003-08-07 |
| US6838095B2 (en) | 2005-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6838095B2 (en) | Ionic silver complex | |
| US3830908A (en) | Anti-microbial compositions utilizing allantoin compounds and complexes | |
| US20020155174A1 (en) | Acidified nitrite as an antimicrobial agent | |
| AU2002312416A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| KR20020038945A (en) | Compositions for prevention and treatment of cold and influenza-like symptoms and their methods of use | |
| AU758264B2 (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
| US20110287113A1 (en) | Treatment of psoriasis | |
| US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| WO2000054593A1 (en) | Iodine preparation compositon | |
| JP3899267B2 (en) | Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders | |
| US20180228837A1 (en) | Stable iodine solutions with medical applications | |
| CN102670648A (en) | Liquid iodine disinfectant, preparation method and used container thereof | |
| US20040009964A1 (en) | Compositions and methods for the treatment of matrix metalloproteinase-related diseases | |
| EP0000670A1 (en) | Therapeutic selenium compositions and the use thereof | |
| MXPA01005900A (en) | Ionic silver complex | |
| JPH10265405A (en) | Skin preparation containing insulin for external use | |
| DE69118796T2 (en) | Scarring pharmaceutical compound | |
| US20090130233A1 (en) | Two part lotion | |
| US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof | |
| JPH1179984A (en) | Liquid for oral and throat disorders | |
| CN110638832A (en) | Nano-silver lidocaine antibacterial pain-relieving plaster and preparation method thereof | |
| CN112352789A (en) | Preparation method of silver chloride ion symbiotic disinfection concentrated solution | |
| CN102727422A (en) | Nano-silver emulsifiable paste and its preparation method | |
| MXPA01009277A (en) | Iodine preparation compositon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |